Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
Healthy Volunteers
ID07244458

Dietary Peanut Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial

Led by Ian J. Neeland, MD · Updated on 2026-04-23

64

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating how eating peanuts every day for 12 weeks may affect weight, diet quality, feelings of fullness, energy, and body composition in adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at least three months. The study aims to understand whether adding peanuts to meals can improve overall health markers such as tiredness and blood levels related to nutrition and metabolism. Participants will be randomly assigned to one of two groups. One group will eat 2 ounces (about 53 grams) of dry-roasted, lightly salted peanuts daily along with their usual diet. The other group will continue their regular diet without peanuts. The study involves dietary supplementation and monitoring over a 12-week period. During the study, participants will have various assessments at the start and end of the 12 weeks. These include surveys measuring hunger, satiety, fatigue, mood, and food enjoyment; reviews of medical records for blood tests like fasting glucose, cholesterol, and HbA1c; and body composition scans using DEXA. Physical activity and dietary quality will also be tracked. Researchers will monitor changes in these measures to evaluate the impact of daily peanut intake.

CONDITIONS

Brief Title

Dietary Peanuts and Nutrition-Related Outcomes

Who Can Participate

Age: 18Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 80 years
  • BMI of 30 kg/m2 or higher, or BMI of 27 kg/m2 or higher with at least one weight-related health condition
  • Have been using semaglutide or tirzepatide for at least 6 months for a clinical indication
Not Eligible

You will not qualify if you...

  • No current use or contraindication to use of GLP-1 receptor agonists
  • Known allergy to nuts
  • Pregnant or breastfeeding
  • Incarcerated

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 weeks

Participants follow their assigned diet, either consuming 2 ounces of dry-roasted, lightly salted peanuts daily along with their regular diet or continuing their regular diet without peanuts.

1 baseline visit and 1 follow-up visit

Trial Site Locations

Total: 1 location

1

University Hospitals Cleveland Medical Center

Clevland, Ohio, United States, 44106

Actively Recruiting

Loading map...

Research Team

I

Ian Neeland, MD

A

Abigail Raffner, PhD, RD, LD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Similar Trials

A Clinical Trial of Tirzepatide (LY3298176) in Subjects With...

Polycystic Ovary Syndrome (PCOS)

Actively Recruiting

2 locations

An Open-label, Randomized, Two-cycle, Two-way Crossover Stud...

Obesity & Overweight

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here